Charles Harvey Kirkpatrick
Physician at Leyden St, Denver, CO
License number
Colorado 14378
Issued Date
Oct 9, 1962
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
295 Leyden St, Denver, CO 80262
Professional information
Dr. Charles H Kirkpatrick, Aurora CO - MD (Doctor of Medicine)
Address:
1635 Aurora Ct, Aurora 80045
(720) 848-1940 (Phone)
12605 E 16Th Ave, Aurora 80045
(720) 848-1940 (Phone)
1635 Aurora Ct, Aurora 80045
(720) 848-1940 (Phone)
12605 E 16Th Ave, Aurora 80045
(720) 848-1940 (Phone)
(720) 848-1940 (Phone)
12605 E 16Th Ave, Aurora 80045
(720) 848-1940 (Phone)
1635 Aurora Ct, Aurora 80045
(720) 848-1940 (Phone)
12605 E 16Th Ave, Aurora 80045
(720) 848-1940 (Phone)
Education:
Medical Schools
University Of Kansas School Of Medicine
Graduated: 1958
University Of Kansas School Of Medicine
Graduated: 1958
Charles H Kirkpatrick, Aurora CO
Specialties:
Allergist
Address:
12605 E 16Th Ave, Aurora, CO 80045
12700 E 19Th Ave, Aurora, CO 80045
12700 E 19Th Ave, Aurora, CO 80045
Education:
University of Kansas, School of Medicine - Doctor of Medicine
University of Colorado Hospital-Anschutz Inpatient Pavilion - Fellowship - Allergy and Immunology
University of Kansas Hospital - Residency - Internal Medicine
University of Colorado Hospital-Anschutz Inpatient Pavilion - Fellowship - Allergy and Immunology
University of Kansas Hospital - Residency - Internal Medicine
Board certifications:
American Board of Allergy and Immunology Certification in Allergy and Immunology, American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Allergy & Immunology (Internal Medicine)
Charles Kirkpatrick, Aurora CO
Work:
University of Colorado Hospital
12605 E 16Th Ave, Aurora, CO 80045 University of Colorado
295 Leyden St, Denver, CO 80262
12605 E 16Th Ave, Aurora, CO 80045 University of Colorado
295 Leyden St, Denver, CO 80262
Characterization Of Transfer Factors And Methods Of Use
US Patent:
5883224, Mar 16, 1999
Filed:
Apr 19, 1996
Appl. No.:
8/635062
Inventors:
Charles H. Kirkpatrick - Denver CO
Martin J. McDermott - Boulder CO
Stephen P. Eisenberg - Boulder CO
Martin J. McDermott - Boulder CO
Stephen P. Eisenberg - Boulder CO
Assignee:
Cytokine Sciences, Inc. - Denver CO
International Classification:
A61K 3808, C07K 706
US Classification:
530328
Abstract:
Characterization of transfer factors is provided in the form of amino acid and nucleic acid sequences corresponding to at least a portion of a conserved transfer factor region. The amino acid and nucleic acid sequences, or functional homologues thereof, are provided along with methods of use thereof for diagnostic, therapeutic and other purposes.
Methods Of Producing Transfer Factor
US Patent:
5840700, Nov 24, 1998
Filed:
May 16, 1995
Appl. No.:
8/441973
Inventors:
Charles H. Kirkpatrick - Denver CO
Stephen J. Rozzo - Aurora CO
Stephen J. Rozzo - Aurora CO
Assignee:
National Jewish Center for Immunology and Respiratory Medicine - Denver CO
International Classification:
C07K 1700
US Classification:
514 21
Abstract:
The invention relates to substantially pure transfer factor with a specific activity of at least 5000 units per absorbance unit at 214 nm. The present invention also relates to a process for preparing the transfer factor from cell lysates. The present invention includes the use of substantially pure transfer factor with a specific activity of at least 5000 units per absorbance unit at 214 nm to treat infectious diseases.
Transfer Factor And Methods Of Use
US Patent:
5470835, Nov 28, 1995
Filed:
Jul 22, 1994
Appl. No.:
8/279278
Inventors:
Charles H. Kirkpatrick - Denver CO
Stephen J. Rozzo - Aurora CO
Stephen J. Rozzo - Aurora CO
Assignee:
National Jewish Center for Immunology and Respiratory Medicine - Denver CO
International Classification:
A61K 3800, C07K 500, C07K 700, C07K 1700
US Classification:
514 21
Abstract:
The invention relates to substantially pure transfer factor with a specific activity of at least 5000 units per absorbance unit at 214 nm. The present invention also relates to a process for preparing the transfer factor from cell lysates. The present invention includes the use of substantially pure transfer factor with a specific activity of at least 5000 units per absorbance unit at 214 nm to treat infectious diseases.